Chapter 25 of 25
- Choose your most important topic
- Select questions for the team
- Bring reports and a support person if wanted
- Leave with a written next step
What you will learn
Separate common myths from evidence; identify the next question relevant to your situation; create a practical appointment checklist.
Prevention and HPV
1. Is cervical cancer preventable?
Many cases can be prevented through HPV vaccination, appropriate screening and treatment of precancer. Prevention greatly reduces risk but does not guarantee that no cervical cancer will occur.
2. Does HPV always cause cancer?
No. Most infections never cause cancer. Persistent high-risk infection and the development of significant cell changes are the main concerns.
3. Can HPV disappear naturally?
It often becomes undetectable through immune control. A negative test does not prove that future detection is impossible, so continue the recommended follow-up.
4. Is cervical cancer contagious?
Cancer itself is not passed between people. HPV can be transmitted through intimate contact, but having HPV is not the same as having cancer.
5. Does a positive HPV test prove infidelity?
No. Infection can remain undetected or become detectable after many years. A result cannot establish when it was acquired or identify a partner as its source.
6. Does poor hygiene cause cervical cancer?
No. Most cervical cancers are linked to persistent high-risk HPV, not cleanliness. Douching and vaginal cleansing do not prevent it and may irritate tissue.
7. Can vaccinated people still develop cervical cancer?
Yes, because vaccines do not cover every cause and may be given after exposure. Screening remains important according to age, history and local guidance.
8. Does vaccination treat an existing HPV infection?
No. It prevents new infection with covered types. An existing positive result or precancer still needs its own follow-up or treatment.
9. Is vaccination only useful before marriage?
No. Benefit relates to age, prior exposure and future exposure, not marital status. Discuss the locally recommended schedule and catch-up options.
10. Should boys be vaccinated too?
Many national programmes include boys to prevent HPV-related disease and transmission. Eligibility and funding vary; check the relevant national recommendations.
Screening and diagnosis
11. Does an abnormal Pap smear mean cancer?
Usually not. It identifies cell changes requiring an appropriate next step, which may be repeat testing, colposcopy or treatment of precancer.
12. Can cervical cancer develop without symptoms?
Yes. Early disease can be silent, which is why screening is offered to people who feel well.
13. Do I need screening after menopause?
Often yes, until the relevant stopping criteria are met. Age alone is insufficient if previous tests are inadequate or there is a high-grade history.
14. Do I need screening after hysterectomy?
It depends on whether the cervix was removed and why, plus previous CIN or cancer. Bring the operation and pathology records rather than assuming screening can stop.
15. Is self-collected HPV testing a home cancer diagnosis?
No. It detects targeted HPV in a vaginal sample using a validated programme. Positive results need a defined follow-up pathway, often involving clinician assessment.
16. Can a normal screen explain new bleeding?
No. New postcoital, intermenstrual or postmenopausal bleeding needs assessment even after a recent reassuring screen.
17. Is a biopsy dangerous because it spreads cancer?
An appropriately performed cervical biopsy is a standard diagnostic procedure. Avoiding an indicated biopsy because of this myth can delay necessary care.
18. Are CIN3 and stage III the same?
No. CIN3 is high-grade precancer in the lining. FIGO stage III describes the extent of invasive cancer.
19. Do positive lymph nodes mean stage IV?
Not necessarily. Pelvic or para-aortic nodal involvement can be stage IIIC under FIGO 2018. Distant spread has a different definition.
20. Can an online tool determine my stage?
No. Stage requires clinical, imaging and pathological information interpreted by the treating team. The explorer explains stages that have already been identified.
Treatment decisions
21. Can cervical cancer be cured?
Many early cancers and many locally advanced cancers can be treated with curative intent. The chance depends on the complete clinical situation and treatment response.
22. Is hysterectomy always necessary?
No. Selected very early cancers may have smaller surgery, while many locally advanced cancers are treated with chemoradiation and brachytherapy rather than hysterectomy.
23. Is simple hysterectomy enough for everyone?
No. Evidence supports it in a carefully defined low-risk group with proper nodal assessment. Larger or higher-risk tumours need different strategies.
24. Is robotic radical hysterectomy always safer?
A quicker recovery does not prove equal cancer outcomes. Randomized evidence favours open surgery when radical hysterectomy is required; discuss the exact operation and evidence.
25. Is chemotherapy always required?
No. Some early cancers are treated with surgery alone. Chemotherapy has particular roles with radiation or in advanced disease, according to risk and fitness.
26. Can chemotherapy replace brachytherapy?
No. In definitive cervical radiotherapy, brachytherapy provides a local dose distribution that additional chemotherapy does not replace.
27. Can an external-beam boost replace brachytherapy?
Generally it should not be treated as an equivalent substitute. If brachytherapy is unavailable locally, ask about referral and explain any exceptional alternative carefully.
28. Does external radiation make me radioactive?
No. You can be near family after external-beam treatment. Temporary high-dose-rate brachytherapy also leaves no source behind after removal; follow your department's specific instructions.
29. Can I receive cisplatin with kidney problems?
It requires individualized assessment. Obstruction, hydration, kidney function and other risks may lead to treatment changes or an alternative, whose evidence may differ.
30. Is immunotherapy suitable for everyone?
No. Disease setting, biomarkers where required, prior therapy, autoimmune or transplant history, fitness and local approval all matter.
31. Does CPS predict my exact chance of response?
No. CPS is a laboratory staining score used for eligibility in certain settings, not an individualized response percentage.
32. Is PD-L1 required for pembrolizumab with chemoradiation?
Not under the verified US FIGO 2014 III–IVA indication. This is different from the CPS requirement for the first-line recurrent/metastatic combination.
33. Are trial results the same as approval everywhere?
No. Regulators, guidelines, reimbursement and availability differ. Ask which local indication supports the proposed drug.
34. Can cervical cancer return?
Yes, despite appropriate treatment. Follow-up and prompt reporting of persistent new symptoms help identify recurrence or treatable late effects.
Recovery and daily life
35. Does radiotherapy affect sexual health?
It can cause dryness, narrowing, pain or menopause. These deserve active care, including pelvic rehabilitation, lubricants and individualized hormone discussions.
36. Can pregnancy be possible after treatment?
Sometimes after carefully selected fertility-sparing treatment. Hysterectomy prevents carrying a pregnancy, and pelvic radiation can damage the uterus and ovaries. Ask before treatment begins.
37. Does preserving ovaries preserve fertility after hysterectomy?
It may preserve hormone function and sometimes eggs, but there is no uterus to carry a pregnancy. Family-building options depend on medical circumstances and local law.
38. Should I avoid all sugar?
No. Restrictive diets can worsen nutrition. A balanced, symptom-adapted plan supports treatment; no diet replaces evidence-based cancer care.
39. Are supplements always safe?
No. Some interfere with treatment, bleeding or kidney function. Give the team a complete list before starting any supplement or herbal product.
40. Does palliative care mean giving up?
No. It manages pain, symptoms and stress and can accompany treatment intended to cure or control cancer.
41. When is fever urgent?
During chemotherapy, a temperature of 38°C or the threshold set by your unit needs immediate oncology contact. Do not wait for a scheduled appointment.
42. Is every new symptom a recurrence?
No. Infection, menopause and treatment effects can cause symptoms too. Persistent or severe changes should be assessed rather than dismissed or assumed to be cancer.
43. Do I need a scan at every follow-up?
Not automatically. Examination, symptoms, risk and the treatment-specific protocol guide testing. Unnecessary imaging can cause false alarms and does not always improve outcomes.
44. How can a caregiver help?
Ask what help is welcome, organize practical tasks, respect privacy and support attendance. Avoid blame, pressure to be positive or unrequested remedies; caregivers also need rest.
Patient appointment checklist
- What is my exact diagnosis, histology and FIGO stage, and which edition is being used?
- Is treatment intended to cure, control disease or relieve symptoms?
- What options fit my disease, health and priorities, and what are their main tradeoffs?
- Do I need fertility or menopause counselling before treatment starts?
- If radiation is planned, where and when will brachytherapy happen?
- What biomarker tests matter, and is the proposed medicine approved and available here?
- How do my previous treatment, kidney function and other illnesses affect the plan?
- Which symptoms require an immediate call, and what is the 24-hour contact number?
- What practical support is available for nutrition, transport, finances, emotional health and caregiving?
- When will results or response be reviewed, and what happens afterward?
Take-home messages
Keep copies of reports and a written next-step plan. Use the question-builder tool to select a topic and print or copy a checklist. Bring uncertainty to the treating team rather than interpreting a single test in isolation.
References and review status
- WHO — Cervical cancer fact sheet
- CDC — HPV vaccination recommendations and considerations
- American Cancer Society — Cervical screening guideline (December 2025 update)
- Cibula et al. ESGO/ESTRO/ESP cervical cancer guidelines, 2023 update
- NCI — Cervical cancer treatment overview
- FDA — Pembrolizumab with chemoradiotherapy, FIGO 2014 III–IVA, January 2024
Evidence/editorial check: 28 October 2026. AI-assisted preparation is separate from physician sign-off. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy